Vyome Biosciences, of New Delhi, India, closed a $14 million series C financing round led by Perceptive Advisors and Romulus Capital along with participation from existing investors including Kalaari Capital, Sabre Partners and Aarin Capital. The company will use the funds predominantly to advance the clinical development of its lead product, VB 1953 for acne, while continuing to develop other products.